Enanta Pharmaceuticals, Inc.
ENTAHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The $382.7M market capitalization puts ENTA squarely in small-cap range for its industry. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Market Cap
$382.7M
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-6.73
EPS (TTM)
$-2.60
EPS (Fwd)
$-1.96
ROE
-59.0%
ROA
-11.8%
Cash
$163.8M
Total Debt
$186.6M
Free CF
$7.7M
52W Change
109.2%
Annual Financials
Cash vs Debt
Enanta Pharmaceuticals, Inc. carries $186.6M in total debt against $163.8M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $7.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -59.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $86.2M (2022) to $65.3M (2025), a 24% decline worth watching.
Investors considering Enanta Pharmaceuticals, Inc. should weigh the typical risks associated with ENTA's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Enanta Pharmaceuticals, Inc. and its sector.